Registration - In-house Corporation

AbbVie Corporation / Tanusree Misra, Vice-President and General Manager

Registration Information

In-house Corporation name: AbbVie Corporation
Previous in-house corporation names
Responsible Officer Name: Tanusree Misra, Vice-President and General Manager
Responsible Officer Change History
Initial registration start date: 2007-04-25
Registration status: Active
Registration Number: 965103-15270

Associated Communications

Total Number of Communication Reports: 172

Monthly communication reports in the last 6 months: 10

Version 48 of 49 (2026-04-16 to 2026-05-13)

Registration versions:

Version 48 of 49 (2026-04-16 to 2026-05-13)

Lobbying Information

Subject Matter Details

Details Regarding the Identified Subject Matter
Subject matters	Details	Categories
Health, Industry, Intellectual Property, International Trade	Communication regarding free trade agreements as they relate to the biopharmaceutical industry.	Policies or Program
Health, Research and Development	Communications regarding access to and approval of medicines addressing the growing public health threat of antimicrobial resistance.	Policies or Program
Health, Research and Development	Communications regarding Health Canada's Regulatory Innovation Agenda regarding proposed regulatory amendments and guidelines to enable agile licensing of drugs and medical devices.	Regulation, Policies or Program
Intellectual Property, International Trade	Communications regarding intellectual property protection of prescription drugs, including the Patent Act, the Patented Medicines Regulations, the Patented Medicine Notice of Compliance (PMNOC) Regulations, the Patent Term Adjustment regime and Health Canada’s Data Protection regime.	Regulation, Policies or Program
Federal-Provincial Relations, Health	Communications regarding national pharmacare legislation, regulations, policies or programs.	Regulation, Policies or Program, Legislative Proposal, Bill or Resolution
Health	Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape.	Policies or Program
Health	Communications regarding the design and implementation of the federal Drugs for Rare Diseases strategy.	Policies or Program
Health	Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.	Policies or Program
Health, Research and Development	Communications with Health Canada regarding guidelines for pediatric action plans.	Policies or Program
Health, Research and Development	Communications with Health Canada regarding modernization of clinical trials regulations, including diversity and inclusivity of clinical trials.	Policies or Program, Regulation
Health	Communications with Health Canada regarding the application of its nitrosamine guidelines.	Policies or Program
Health, Research and Development	Communications with Health Canada regarding the evolution of the regulatory framework to address advanced therapeutic products.	Policies or Program, Regulation
Health, Research and Development	Communications with Heath Canada regarding modernization of the medical devices regulatory framework.	Regulation, Policies or Program
Health, International Trade	Engagement with Health Canada’s Regulatory Operations & Enforcement branch regarding supply chain resilience & integrity; mitigating and alleviating drug shortages.	Policies or Program
Aboriginal Affairs, Health	Federal Government Non Insured Health Benefits program with respect to reimbursement of a prescription medicine and changes in type of reimbursement	Policies or Program
Economic Development, Industry, Research and Development	Innovation, Science and Economic Development (ISED)'s Health Emergency Readiness program, insofar as it pertains to growth and development of the life sciences industry in Canada.	Policies or Program
Economic Development, Health, Industry, Intellectual Property	Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada.	Policies or Program
Aboriginal Affairs, Health	Public Health Agency of Canada, regarding the federal response to the hepatitis C virus.	Policies or Program
Health	The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.	Policies or Program

Communication Techniques

Written communication
Oral communication

Government Institutions

Atlantic Canada Opportunities Agency (ACOA)
Canadian Institutes of Health Research (CIHR)
Correctional Service of Canada (CSC)
Employment and Social Development Canada (ESDC)
Finance Canada (FIN)
Global Affairs Canada (GAC)
Health Canada (HC)
House of Commons
Immigration and Refugee Board (IRB)
Indigenous Services Canada (ISC)
Innovation, Science and Economic Development Canada (ISED)
Intergovernmental Affairs Secretariat (IGA)
Invest in Canada Hub
National Defence (DND)
National Research Council (NRC)
Patented Medicine Prices Review Board (PMPRB)
Prime Minister's Office (PMO)
Privy Council Office (PCO)
Public Health Agency of Canada (PHAC)
Public Services and Procurement Canada (PSPC)
Royal Canadian Mounted Police (RCMP)
Senate of Canada
Treasury Board Of Canada Secretariat (TBS)
Veterans Affairs Canada (VAC)

In-house Corporation Details

Description of activities

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.ca.

Responsible officer name and position during the period of this registration

Arima Ventin, Head, Market Access and Government Affairs

Government funding

No government funding was received during the last completed financial year.

In-house Corporation Contact Information

Address:
8401 Transcanada Highway
St-Laurent, QC H4S 1Z1
Canada

Telephone number: 416-201-1757

Parent Company Information

AbbVie Inc.
- 1 N. Waukegan Road
  North Chicago, IL 60064
  United States of America

Subsidiary Beneficiary Information

AbbVie Corporation does not have any subsidiaries that could have a direct interest in the outcome of the undertaking

Lobbyists Details

Senior officers whose lobbying activities represent less than a significant part of their duties

Herve Gaboury, Head, Market Access & HEOR, Oncology | No public offices held
Judith Mergl, Director, Regulatory Affairs | No public offices held
Stephanie Sauvageau, Head, Medical Affairs | No public offices held
Arima Ventin, Head, Market Access and Government Affairs | No public offices held

Senior officers and employees whose lobbying activities represent a significant part of their duties

Sean Awalt, Manager, Market Access and Government Affairs, Atlantic | No public offices held
Adam Cook, Manager, Market Access and Government Affairs, Ontario & Federal Programs | No public offices held
Dana Corsen, Field Lead, Market Access & Government Affairs, Immunology | No public offices held
Lauren Fischer, Lead, Government Affairs & Policy | No public offices held
Jean-Luc Fortier, Manager, Market Access and Government Affairs, Quebec | No public offices held
Harold Just, Manager, Market Access and Government Affairs - Oncology | No public offices held
David Link, Field Lead, Market Access & Government Affairs - Specialty | No public offices held
Reema Malhotra, Field Lead, Market Access & Government Affairs - Oncology | No public offices held
Jeff Onyskiw, Sr Manager, Market Access & Government Affairs – Saskatchewan, Manitoba, Federal Plans, Territories | No public offices held
Eric Pegolo, Manager, Market Access and Government Affairs, Ontario | No public offices held

AbbVie Corporation

The following names have been used on or after July 2, 2008

Name	From	To
AbbVie Corporation	2013-04-25	current
Abbott Laboratories	2008-07-02	2013-04-25

The following names have been used before July 2, 2008

Abbott Laboratories
Abbott Laboratories, Limited

AbbVie Corporation

Responsible Officer History
Responsible Officer Name	From (YYYY-MM-DD)	To (YYYY-MM-DD)
Tanusree Misra	2026-05-13	Current
Arima Ventin	2026-02-01	2026-05-13
RAMI FAYED	2024-02-01	2026-02-01
Tracey Ramsay	2021-02-01	2024-02-01
Denis Hello	2020-03-01	2021-02-01
Stéphane Lassignardie	2015-01-05	2020-03-01
Felipe Pastrana	2011-04-01	2015-01-05
Jeffrey Devlin	2007-04-25	2011-04-01

Date Modified:: 2026-05-11

Search and menus

Language selection

Registration - In-house Corporation

AbbVie Corporation / Tanusree Misra, Vice-President and General Manager

Registration Information

Associated Communications

Version 48 of 49 (2026-04-16 to 2026-05-13)

Version 48 of 49 (2026-04-16 to 2026-05-13)

Subject Matter Details

Communication Techniques

Government Institutions

Description of activities

Responsible officer name and position during the period of this registration

Government funding

In-house Corporation Contact Information

Parent Company Information

Subsidiary Beneficiary Information

Senior officers whose lobbying activities represent less than a significant part of their duties

Senior officers and employees whose lobbying activities represent a significant part of their duties